Literature DB >> 3290402

Acute vascular rejection involving the major coronary arteries of a cardiac allograft.

R L Yowell1, E H Hammond, M R Bristow, F S Watson, D G Renlund, J B O'Connell.   

Abstract

A case of acute vascular rejection occurring in a cardiac allograft is presented. The rejection was characterized by prominent lymphocytic infiltration of the major coronary arteries in a pattern similar to that observed in acute vascular rejection occurring in renal allografts. Additionally, there was electron microscopic evidence of endothelial damage of smaller vessels. In addition to routine light microscopic evaluation of heart biopsies obtained in this case, immunofluorescent staining of biopsies for IgG, IgM, C3, Clq, fibrinogen, T cells, B cells, and Ia human leukocyte antigen (HLA-DR) was also performed. These studies suggest that antibodies may have been important in the terminal rejection episode described in this case. Furthermore, immunofluorescent staining detected continuing endothelial cell damage, reflected as Ia antigen positivity of allograft blood vessels, despite apparent improvement of rejection as judged by light microscopy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3290402

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  3 in total

1.  HIV-associated myocarditis. Pathology and immunopathology.

Authors:  W E Beschorner; K Baughman; R P Turnicky; G M Hutchins; S A Rowe; A L Kavanaugh-McHugh; D L Suresch; A Herskowitz
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

Review 2.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

3.  Accelerated arteriosclerosis in heart transplant recipients is associated with a T-lymphocyte-mediated endothelialitis.

Authors:  R H Hruban; W E Beschorner; W A Baumgartner; S M Augustine; H Ren; B A Reitz; G M Hutchins
Journal:  Am J Pathol       Date:  1990-10       Impact factor: 4.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.